FHTX
Foghorn Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$303.48M
P/E Ratio
—
EPS
$-1.18
Beta
3.11
52W High
$6.95
52W Low
$3.27
50-Day MA
$5.20
200-Day MA
$5.10
Dividend Yield
—
Profit Margin
-240.30%
Forward P/E
—
PEG Ratio
—
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $30.91M |
| Gross Profit (TTM) | $-54.56M |
| EBITDA | $-78.78M |
| Operating Margin | -211.90% |
| Return on Equity | -470.40% |
| Return on Assets | -21.30% |
| Revenue/Share (TTM) | $0.49 |
| Book Value | $-1.92 |
| Price-to-Book | 2005.35 |
| Price-to-Sales (TTM) | 9.82 |
| EV/Revenue | 6.01 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 223.80% |
| Shares Outstanding | $58.70M |
| Float | $28.68M |
| % Insiders | 17.99% |
| % Institutions | 72.03% |
Historical Volatility
HV 10-Day
61.08%
HV 20-Day
56.21%
HV 30-Day
58.38%
HV 60-Day
61.02%
HV Rank
7.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.44 target)
1
Strong Buy9
BuyData last updated: 4/29/2026